Clinical remission after unilateral adrenalectomy to treat unilateral primary aldosteronism is achieved in less than half of patients. A linear discriminant model with 6 presurgical predictors of clinical remission was used to build a 25-point prediction score of postsurgical clinical outcomes.
INTRODUCTION
Primary aldosteronism (PA) is a frequent cause of endocrine hypertension with prevalence estimates ranging from 5-15% in the general population with hypertension 1-3 and as high as 20% in patients with resistant hypertension 4 . The overproduction of aldosterone is mainly caused by a unilateral aldosterone-producing adenoma or bilateral adrenal hyperplasia which are specifically treated by laparoscopic adrenalectomy or with a mineralocorticoid receptor antagonist, respectively [5] [6] . The deleterious effects of excessive aldosterone production on cardiovascular, cerebrovascular and renal function highlight the importance of an early diagnosis and initiation of specific treatment strategies for unilateral and bilateral forms of PA [7] [8] [9] [10] .
The differentiation of unilateral from bilateral forms is achieved by computed tomography (CT) or adrenal venous sampling (AVS). AVS is the recommended approach by the Endocrine Society Guideline 11 because of the lack of specificity and sensitivity of CT [12] [13] . The objective of adrenalectomy is to resolve excessive aldosterone production, normalize plasma potassium concentrations (if the patient was hypokalemic pre-surgically), and to normalize or at least improve the elevated blood pressure which is characteristic of the disorder. Although more than 4 in every 5 patients with unilateral PA experience a clinical benefit from surgery 14 , the proportion of patients with clinical remission with normalization of blood pressure without the aid of antihypertensive medication represents 16-72% [14] [15] [16] [17] [18] [19] .
Several studies have identified presurgical predictors of clinical cure (complete clinical success 14 ) such as younger age, female sex, shorter duration of hypertension before surgery, number of antihypertensive drugs, low serum potassium and high urinary aldosterone levels 14, 18, 20, 21 .
A prediction score for the resolution of hypertension after surgery has been developed 17 which also performed well in a patient cohort from Japan 22 but not in a French population 23 . The aldosteronoma resolution score is based on a points system to predict 3 levels (low, medium, high) of likelihood of clinical cure. A positive predictive value of 75.0% (9 of 12 patients) was achieved with the validation dataset at the high likelihood level albeit with a low sensitivity of 31.0% (9 of 29 patients with clinical cure were accurately predicted). The negative predictive value of the lowest likelihood score was 72.4% (21 of 29 patients) with a specificity of 55.3% (21 of 38 patients) 17 .
We developed a prediction score (PASO [Primary Aldosteronism Surgical Outcome] score) for complete clinical success after adrenalectomy for unilateral PA using patient data from a large multicenter cohort with outcomes assessed in accordance with a standardized set of criteria 14, 24 . The PASO score requires input of 6 presurgical variables and can be calculated either manually or with an online tool (PASO predictor) to facilitate the use of the prediction score in the clinical setting. To provide additional information on the probability of a complete, partial or absent clinical outcome, the PASO predictor also computes the proportion of patients from the multicenter cohort in each outcome group. The PASO score can be used by clinicians for the management of patient expectations of post-surgical clinical outcomes and to identify which patients will need close follow up due to persistent hypertension.
METHODS

Study Cohort
Patient data from the PASO study 14 were used to train and validate a predictive model for clinical outcomes after adrenalectomy for unilateral PA. Variables associated with complete clinical success were selected from unadjusted and adjusted logistic regression models (Table 1 ) and all patients without missing values for these variables were included for further analyses (n= 380). The clinical characteristics of the study cohort are reported in Table 2 . These patients were a subset of 8 City because written consent for the analysis of patient data is not required in Japan.
PA was diagnosed in accordance with the US Endocrine Society or the Japan Endocrine Guideline 11, 25 . Unilateral PA was differentiated from bilateral PA by adrenal venous sampling in all patients before adrenalectomy. Clinical and biochemical outcomes were classified as complete, partial and absent success, and were evaluated in accordance with the PASO consensus 14 . Clinical outcomes were defined by blood pressure measurements and antihypertensive medication dosages. Patients with complete clinical success comprise those with normalized blood pressure levels without the use of antihypertensive medication after surgery. Biochemical outcomes were defined according to serum potassium concentrations and the aldosterone-to-renin ratio (ARR). Patients with normalization of hypokalemia (if present pre-surgery) and normalization of the ARR were classified as complete biochemical success. Further details on the criteria defining clinical and biochemical outcomes are described elsewhere 14 .
Linear Discriminant Analysis
Linear discriminant analysis (LDA) was performed using MATLAB R2017b software on the combined cohort (n = 380 patients) employing linear combinations of variables to maximize the separation between groups by increasing precision estimates by variance reduction 26, 27 . LDA models have been widely exploited in the context of prediction modelling for clinical research as described previously [28] [29] [30] [31] [32] Table 2 , whereas normalized coefficients are represented in Figure 1C .
The combination of variables which gave the best accuracy of classification of complete clinical success versus partial and absent success combined was selected by the algorithm and the performance of the LDA model was assessed by 10-fold cross validation. The 10-fold cross validation analysis randomly divides the cohort into 10 subgroups. The model is trained with the first 9 subgroups, the remaining group is used for validation. The validation group is then changed and accordingly the training groups. The process is repeated a total of 10 times with the validation group rotating at each round and the remaining subgroups used for model training.
Prediction score
The 6 variables selected by the LDA model were used to develop a 25-point prediction score (PASO score); variables were categorized using the MATLAB R2017b software algorithm and cut-offs were automatically derived to achieve the best accuracy; points were assigned on the basis of discriminant analysis normalized coefficients and ORs from the adjusted regression analyses.
The PASO score was generated using a training dataset (n= 280) and validated on the test dataset (n= 100). A receiver operating characteristic (ROC) curve was used to assess the area under the curve (AUC) and the best cut-off to discriminate complete versus (partial + absent) clinical success after adrenalectomy was automatically defined by the software (MATLAB R2017b) algorithm and confirmed by evaluation of the Youden Index (J = sensitivity + specificity -1). An online tool was developed that automatically calculates the defined daily dose (DDD), the score and the predicted clinical outcome (PASO predictor available at https://github.com/ABurrello/PASO-Predictor/raw/master/00%20-%20PASO%20Predictor.xlsm
Statistical Analyses
IBM SPSS Statistics 24 (IBM Corp. Armonk, New York, USA) was used for statistical analyses. The normally distributed variable (BMI) is expressed as the mean ± SD and analyzed by a one-way ANOVA test; non-normally distributed variables (duration of hypertension, DDD, nodule diameter) are expressed as medians and interquartile range and analyzed using the Mann-Whitney's test.
Categorical variables (sex, target organ damage) are expressed as absolute numbers and proportions (%) and analyzed by a chi square test. Unadjusted and adjusted logistic regression analyses were used to determine odds ratios (ORs) for the 6 variables selected by the LDA on the combined cohort (n= 380 patients). An OR greater than 1 indicates an increased likelihood of complete clinical success, an OR less than 1, a decreased likelihood. Correlations were evaluated by a Pearson test. A P-value of less than 0.05 was considered significant.
RESULTS
LDA prediction model
The cohort included 380 surgically-treated patients for unilateral PA with complete datasets (see Table 2 for patient characteristics). Complete clinical success was achieved in 150 of the 380 patients (39.5%), partial or absent clinical success in 173 (45.5%) and 57 patients (15%), respectively.
Complete biochemical success was achieved in 357 of 380 (93.9%) patients, with a further 16 (5.2%) and 7 (1.8%) patients displaying partial or absent biochemical success after surgery, respectively.
Using unadjusted univariate and adjusted multivariate analyses, we selected the variables with the strongest association with complete clinical success (Table 1 ). In the unadjusted analysis, all selected variables were significantly associated with complete clinical success (P < 0.001) except largest nodule size. In the adjusted model, duration of hypertension (OR 0.99 per month; CI 95% 0.98-0.99; P < 0.001), sex (reference female; OR 2.91; 95% CI 1.74-4.86; P = < 0.001), DDD (OR 0.81 per unit increase; 95% CI 0.72-0.92; P = 0.001), target organ damage (reference presence; OR 2.84; 95% CI 1.69-4.78; P < 0.001) and largest nodule at imaging (OR 1.03 per mm; 95% CI 1.01-1.06; P = 0.048) were all confirmed as independent predictors.
The combination of variables with the best accuracy of prediction of complete clinical success versus (partial + absent) success was used in the LDA model. The variables were known duration of hypertension (months), sex (female/male), BMI (Kg/m 2 ), antihypertensive medication (defined by DDD), presence of target organ damage (left ventricular hypertrophy and/or microalbuminuria) and largest nodule size at imaging (diameter, mm). Known duration of hypertension had a greater predictive performance than age (a correlated confounding variable) and was selected for inclusion.
The linear combination of variables included in the LDA is shown in the canonical plot ( Figure 1A) .
Each point represents a patient and the distribution of clinical outcomes indicates that the model can distinguish complete from partial + absent clinical success combined whereas patients with partial clinical success cannot be differentiated from those with absent success.
The LDA model correctly predicted the outcomes of 293 of 380 patients (77.1% accuracy) with a sensitivity of 69.3% and a specificity of 82.2% ( Figure 1B ). In detail, 104 of 150 and 189 of 230 patients were correctly assigned to the complete and the partial + absent clinical success groups, respectively. To exclude overfitting and to assess how the prediction could generalize in an independent cohort, the LDA model was validated by 10-fold cross validation analysis that confirmed a high predictive performance with an accuracy of 75.3% (with cross validation), compared with 77.1% (with the LDA model), thus excluding any risk of bias. In the LDA model, the strongest predictor of complete clinical success was known duration of hypertension (LDA normalized coefficient equal to 1.0), followed by antihypertensive medication and largest nodule size at imaging (0.8 and 0.5, respectively; Figure 1C and Supplemental Digital Content Table 2 that shows the normalized LDA coefficients for each of the 6 variables).
PASO score
Patients included in the LDA model (n = 380) were randomly assigned to a training dataset (n = 280) and a test dataset (n = 100). There were no differences in clinical outcomes or in any of the 6 variables used in the LDA model between the 2 cohorts (see Supplemental Digital Content Table 1 for a comparison of the training and test datasets). Figure 2D ). With validation of the score using the test dataset, 73 of 100 patients were correctly classified (accuracy 73%). The predictive performance on the combined cohort was still higher than the LDA model, with correct classification of 301 of 380 patients (accuracy, 79.2%; sensitivity, 71.3% and specificity, 84.4%) ( Figure 2D ). Positive and negative predictive values were respectively 74.8% and 81.6% ( Table 3) . The difference between the accuracy of the PASO score in the training dataset and in the test dataset (81.4% and 73.0%, respectively) revealed a modest bias due to the effect of overfitting (best performance of the model in the cohort in which it is trained), which was expected and did not affect the reliability of the model.
As expected, the PASO score was directly correlated with the proportion of patients with complete clinical success (R = 0.940; P < 0.001) ( Figure 3 ). Supplemental Digital Content Table 3 shows patients in the combined cohort stratified for clinical outcomes and for PASO score. Patients with a score of 24.1-25 all had complete clinical success after surgery (n = 9); a single patient with a score of 0-2.0 had partial clinical success. For patients with a PASO score equal to or greater than 20, complete clinical success was correctly predicted in 58 of 69 patients (positive predictive value 84.1%; Table 3 ). For patients with a PASO score less than 10, partial and absent clinical success combined was correctly predicted in 72 of 77 patients (negative predictive value 93.5%; Table 3 ).
The LDA model was adapted to predict all patients with a potential clinical benefit after surgery. For this we attempted to develop 2 additional models: (complete + partial) versus absent clinical success and complete versus partial versus absent clinical success. For the prediction of (complete + partial) versus absent clinical success, we achieved an accuracy of 85.3% and 71.8% for the LDA model and the PASO score (on the combined cohort), respectively but this was achieved with very low specificity (Supplemental Digital Content Table 4 ). For the prediction of complete versus partial versus absent clinical success, the model attained moderate accuracy (63.4% for the LDA model and 55.3% for the PASO score on the combined cohort; Supplemental Digital Content Table 5 ). The low performance of these two additional models is because of the difficulty in distinguishing patients with Table 6 ).
Finally, we assessed the generalizability of our model for each center included in the analysis. We found no significant differences for the accuracies of the LDA model and the PASO score (P = 0.284 and P = 0.188, respectively) applied to patients stratified by center (Supplemental Digital Content Table 7 ).
DISCUSSION
The optimal treatment for unilateral forms of PA is laparoscopic adrenalectomy which should remove the source of aldosterone overproduction and potentially cure the disorder. There is a wide variability in clinical outcomes with usually less than half of patients in a given center achieving complete clinical success after surgery with normalization of blood pressure without the aid of antihypertensive medication 14, 17, 18, 33 . A substantial proportion of patients (35-66%) have a partial clinical response to adrenalectomy (partial clinical success) and the absence of clinical benefit (absent clinical success)
is found in 0-32% 14 . Several factors influence clinical outcomes after adrenalectomy such as sex, age, concurrent primary hypertension and long-standing PA 14, 18, 20, 21, 34 . Presurgical factors associated with clinical outcomes can be exploited to develop prediction scores to provide objective measures of clinical outcomes and, if reliable, used to counsel patients on the probability of a surgical cure versus a lifetime of antihypertensive medication.
In this study we developed a prediction tool, the PASO predictor, for clinicians to differentiate patients with unilateral PA with a complete clinical response to unilateral adrenalectomy from those with a partial and absent response combined. Although not achieving clinical cure, patients with partial clinical success after unilateral adrenalectomy obtain substantial clinical benefits but will need continuous surveillance after surgery due to remnant hypertension. The PASO predictor may help clinicians evaluate the benefits of surgery and inform patients on their expected post-surgical outcomes as well as identifying which patients require close follow up.
A prediction score (Aldosteronoma Resolution Score) was developed previously based on a points system using 4 readily available variables (number of antihypertensive drugs, duration of hypertension, sex and BMI) 17 . We developed an improved prediction score (PASO score) using patient data from a multicenter international cohort. Applying the PASO score to the combined dataset in the present study gave a positive predictive value of 84.1% (58 of 69 patients) using the highest level for likelihood of complete clinical success (≥ 20 points) and a negative predictive value of 93.5% (72 of 77 patients) for the lowest likelihood level (≥ 10 points). This compares favorably with the previously published aldosteronoma resolution score which, in the total dataset, had a positive predictive value of 80.0% (28 of 35 patients) for the highest likelihood of clinical cure (4-5 points) and a negative predictive value of 86.3% (63 of 73 patients) for the lowest likelihood level (0-1 points) 17 . Our validation of the score indicated an accuracy of prediction of 73.0% (72.5% sensitivity and 73.3% specificity) compared with an accuracy of 65.7% with the validation dataset of the aldosteronoma score (sensitivity, 31.0%; specificity, 92.1%).
Our score is more complex than the aldosteronoma resolution score. The LDA model identified 2 variables (largest nodule size at imaging and target organ damage evaluated by microalbuminuria and/or left ventricular hypertrophy) in addition to the same 4 variables used in the aldosteronoma resolution prediction score. These 2 variables were included because target organ damage displayed a better predictive performance than BMI; and nodule size performed better than both target organ damage and sex. Adrenal CT or MRI and target organ damage should be evaluated in all patients with PA because the possibility of an aldosterone-producing carcinoma requires exclusion by imaging 11 and the routine assessment of microalbuminuria and left ventricular hypertrophy is recommended in all patients with hypertension 35 . Evaluation of target organ damage to the kidneys and heart is particularly relevant in patients with PA because of their increased risk (which can be reversed with appropriate treatment) relative to patients with primary hypertension 7, 8, 10, [36] [37] [38] .
A prediction score that separates partial from an absent clinical outcome would also be useful because patients with a partial clinical outcome derive clinical benefits from surgery, potentially attaining a substantial improvement in hypertension status or antihypertensive drug requirements (possibly achieving normalization of blood pressure although with the aid of antihypertensive medication). The LDA model described herein could not separate the partial from absent clinical success groups.
However, to partially address this need, the PASO predictor indicates the probability of achieving each clinical outcome by calculating the proportion of patients with complete, partial and absent clinical success for the PASO score based on the clinical outcomes of the total cohort.
The strengths of our study include the multicenter inclusion of a large number of patients from a wide geographical spread and the high performance of the PASO score using a validation test which indicated the general applicability of the score. We also developed a user-friendly online tool to calculate the PASO score which automatically converts antihypertensive medication dosages to DDDs (a standardized measure of medication) and predicts the likelihood of complete clinical success after adrenalectomy as well as those patients in the partial and absent clinical success groups combined that require close post-surgical follow up. A potential limitation of the prediction score is the increased number of input variables relative to previous models with the requirement of adrenal imaging data and assessment of target organ damage which are nonetheless widely considered essential evaluations in patients with PA. Another limitation is the inability of the prediction score to differentiate patients with a clinical benefit after surgery (complete + partial from absent or complete versus partial versus absent clinical success), but the PASO predictor calculates the probability of each clinical outcome at any given PASO score which, although not a prediction score, can be used to advice patients on their likely clinical outcomes.
In conclusion, we developed a score system based on presurgical factors, integrated into an online tool, to reliably predict complete clinical success after adrenalectomy and to guide the clinical management of patients with PA. Logistic regression analyses were performed to assess the odds ratios (OR) and 95% confidence intervals (CI) for the six variables selected by the LDA model. The unadjusted univariate and adjusted multivariate ORs are shown as indicated. An OR greater than 1 indicates an increased likelihood of complete clinical success (clinical cure) and an OR less than 1 a decreased likelihood. Patient data from the total cohort (n = 380) were included in the models. BMI (body mass index), DDD (defined daily dose), duration of hypertension and largest nodule at imaging were treated as continuous variables; sex and target organ damage were treated as categorical variables. AntiHT medication, antihypertensive medication.
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults (https://www.whocc.no/atc_ddd_index/). The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults (https://www.whocc.no/atc_ddd_index/). Table 3 shows the actual numbers and proportion of patients in each stratification level. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults (https://www.whocc.no/atc_ddd_index/). Table 3 Distribution of patients with unilateral primary aldosteronism stratified by clinical success after adrenalectomy and PASO score Score Total The number (n) and proportion (%) of patients stratified for clinical success (complete, partial, absent) and PASO score is shown in the combined cohort (n = 380). N.A., not applicable. Panel A, shows the real and predicted clinical outcomes, the accuracy, sensitivity, specificity and 10fold cross validation of the LDA model.
Supplemental Digital Content
Panel B, shows the real and predicted clinical outcomes, accuracy, sensitivity and specificity for the training dataset (n = 280), test dataset (n = 180) and the combined cohort (n = 380) for the PASO score. A cut-off of greater than 10 points identifies patients with complete + partial clinical success.
